Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

First biomarker test for the diagnosis of osteoarthritis

Country of Origin: Germany
Reference Number: TODE20180515001
Publication Date: 15 May 2018

Summary

A German university offers autoantibodies that improve the diagnosis of osteoarthritis. It is the first serum biomarker test in this context. Partners from the medical diagnostic industry are sought for license agreements as well as a technical cooperation agreement.

Description

Osteoarthritis (OA) is the most common degenerative disease of joints world-wide. About two-third of people over 65 years are affected, whereas the etiology is largely unclear. Currently, there is no causative therapy available, which is due to the complex pathomechanisms of arthrosis and also due to the lack of diagnostic biomarkers that allow monitoring of therapeutic success of drug candidates. 

Researchers of a German university have found that autoantibodies against the cartilage protein thrombospondin 4 (TSP-4) occur in the course of arthrosis. Rheumatoid arthritis is characterized by the presence of autoantibodies, but autoantibodies against TSP-4 have not yet been described for arthrosis.

In addition to TSP-4, the researchers have found autoantibodies against the cartilage oligomeric matrix protein (COMP) and the C-type lectin domain family 3 member A (CLEC3A) in the course of OA, which may be used in a combined test together with TSP-4 in order to strengthen significance of diagnosis (Table 1). Thus the present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA.

The university offers a license agreement to companies in the medical diagnostic sector. The university also offers a technical cooperation agreement because the biomarker is in an early development stage and needs to be develeoped into an operable routine test.
Image

Advantages and Innovations

The present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA and furthermore it may provide a tool that allows the monitoring of therapeutic success of drug candidates for the treatment of arthrosis.

Stage Of Development

Field tested/evaluated

Stage Of Development Comment

Further patient trials need to be done

Requested partner

The university offers a license agreement to companies in the diagnostic sector (analysing blood) or companies offering supplies/ materials for blood analysis. The biomarker is in an early development stage and further patient trials need to be done. Hence the university also offers a technical cooperation agreement in order to develop the existing test into an operable routine test.

Kooperationsanfrage stellen